Neurocrine shares fell 8% after mixed earnings, strong Ingrezza sales, and a 2026 outlook that met expectations. Analysts see ...

Q4 2025 Management View CEO Kyle Gano highlighted that "As Neurocrine enters 2026, our foundation is stronger than at any ...

Neurocrine Biosciences reported largely in-line Q4 results, with better-than-expected Crenessity sales. Click here to read my ...

Neurocrine Biosciences, Inc. leverages a strong cash position and a neuropsychiatry pipeline to drive long-term commercial growth. See why NBIX stock is a buy.

Neurocrine Biosciences (NASDAQ:NBIX) executives said the company is entering 2026 with what Chief Executive Officer Kyle Gano ...

For the full year 2025, Neurocrine reported total net product sales of $2.83 billion, a 22% increase from the previous year. INGREZZA sales grew 9% to $2.51 billion, while CRENESSITY, which was ...

As Neurocrine enters 2026, our foundation is stronger than at any point in our more than 30-year history and it continues to ...

Last year, Neurocrine’s Ingrezza failed a phase 2 trial in pediatric Tourette Syndrome patients, prompting the company to use what it learned in designing a new phase 2b. But now Ingrezza has flunked ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...

Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected. The company has slapped a $5,275 sticker on a 30-count bottle of 40 mg capsules of the ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings. The company on Monday reported adjusted EPS of ...

Neurocrine Biosciences stock closed up nearly 25 percent Wednesday, after the San Diego biotech company announced the approval of Ingrezza, its movement disorder drug. Neurocrine closed at $51.80, up ...